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Pole of Transtelephonic Electrocardiographic
onitoring in Detecting Short-Term
rrhythmia Recurrences After Radiofrequency
blation in Patients With Atrial Fibrillation
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OBJECTIVES The aim of our study was to determine the incidence of asymptomatic recurrences of atrial
fibrillation (AF) by daily transtelephonic (TT) electrocardiographic (ECG) monitoring, as
compared with standard ECG and 24-h Holter recording, in patients who underwent
radiofrequency catheter ablation (RCA) of AF.
BACKGROUND The efficacy of RCA of AF is usually evaluated by means of patients’ symptoms.
METHODS Seventy-two patients with paroxysmal (n  37) or persistent (n  35) drug-refractory AF
underwent circumferential RCA of the pulmonary vein (PV) ostia. Left isthmus ablation was
performed in 57 patients, and cavotricuspid isthmus ablation was done in 69 patients. Patients
were scheduled to obtain an ECG and Holter recordings one and four months after ablation,
as well as a daily TT ECG, from 30 to 120 days after ablation or in the event of symptoms.
RESULTS A total of 5,585 TT ECGs were obtained (mean 77.5 per patient). In 20 patients (27.8%),
AF recurrences were recorded during TT ECG, whereas ECG and Holter monitoring
revealed AF recurrences in 10 patients (13.9%, p  0.001). Ten patients had at least one
asymptomatic AF recurrence, and eight were completely asymptomatic. The ECG recorded
in the event of symptoms always showed AF.
CONCLUSIONS Transtelephonic ECG is better than standard ECG and 24-h Holter recordings in evaluating
AF relapses after RCA, thus decreasing the short-term success of ablation from 86% to 72%.
The absence of symptoms should not be interpreted as absence of AF, as 50% of patients were
asymptomatic during at least one AF episode. (J Am Coll Cardiol 2005;45:873–6) © 2005
























atrial fibrillation (AF) is the most common sustained
rrhythmia and is associated with substantial morbidity that
s primarily related to symptoms, heart failure, and throm-
oembolic events (1). Radiofrequency catheter ablation
RCA) has recently been proposed as an alternative treat-
ent for drug-refractory paroxysmal and persistent AF. The
uccess rate of catheter ablation has been mainly based on
atients’ symptoms or routine electrocardiograms (ECGs)
r 24-h Holter recordings. However, asymptomatic recur-
ences of AF may remain undetected. When routine trans-
elephonic (TT) ECG recordings are performed, the inci-
ence of asymptomatic AF may be as high as 20% (2,3), and
reatment of AF with drug therapy may contribute to this
ncidence by providing rate control during recurrence or by
hortening the duration of the recurrence (4). The aim of
ur study was to determine the incidence of asymptomatic
F recurrences, using daily TT ECG monitoring, in the
hort-term follow-up of patients with paroxysmal or persis-
ent AF undergoing catheter ablation.
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atient population. Seventy-two of 97 consecutive pa-
ients who underwent catheter ablation of AF met the
nclusion criteria and were willing to give consent, and thus
ere enrolled. Inclusion criteria included: 1) symptomatic
rug-refractory AF (at least two anti-arrhythmic drugs
ttempted); 2) paroxysmal AF with documented monthly
ustained episodes; and 3) persistent AF in patients who had
lready undergone three or more electrical cardioversions.
tudy protocol. All patients gave informed, written con-
ent to be enrolled in the study. A detailed clinical exami-
ation, thyroid function tests, ECG, chest radiography,
olter monitoring, and transthoracic and transesophageal
chocardiography were routinely performed. All patients
ere treated with oral anticoagulation using warfarin so-
ium to achieve an international normalized ratio of 2 to 3
or three weeks before catheter ablation. All patients under-
ent ablation while receiving the best anti-arrhythmic
reatment. After ablation, cardiac rhythm was monitored by
elemetry for at least 4 h and 12-lead ECG was performed
t 12, 24, and 36 h after ablation. Clinical examination and
2-lead ECG were scheduled after hospital discharge, at
ne week, and at 14, 30, and 120 days. Thirty days after
blation, patients received a TT ECG recorder (CG2206
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AF Ablation Follow-Up March 15, 2005:873–6btain a daily 30-s TT ECG for the next 90 days and a
urther TT ECG record in case of symptomatic palpita-
ions. A 24-h Holter recording and transthoracic echocar-
iogram were scheduled 30 and 120 days after ablation,
hereas transesophageal echocardiography was usually per-
ormed three to four months after ablation to assess the
ccurrence of pulmonary vein (PV) stenosis. After ablation,
atients were discharged on oral anticoagulation and anti-
rrhythmic therapy for at least four months.
apping and ablation procedure. The mapping and ab-
ation strategy has been already described (5). Briefly, the
eft atrium and PVs were explored using a transseptal
pproach. Real-time three-dimensional left atrial maps were
econstructed using a nonfluoroscopic navigation system
CARTO, Biosense Webster, Los Angeles, California),
cquiring a minimum of 60 points. The ostium of the PVs
as identified by fluoroscopic visualization of the catheter
ip entering cardiac silhouette, during withdrawal of the
atheter from the PV, with a simultaneous impedance
ecrease and appearance of atrial potential. In patients in
inus rhythm at the beginning of the procedure, maps were
cquired during pacing from the coronary sinus. In patients
n AF, maps were acquired to assess the amplitude of the
ocal atrial electrograms. Radiofrequency pulses were deliv-
red using a 3.5-mm (with a temperature setting up to 45°C
nd radiofrequency energy up to 50 W) cooled-tip catheter.
adiofrequency energy was delivered for 60 to 120 s until
he local electrogram amplitude was reduced 80%. The
blation lines consisted of a contiguous focal lesion deployed
t a distance 5 mm from the ostia of the PVs, creating a
ircumferential line of conduction block around each PV.
he remap process was performed in all patients in sinus
hythm, utilizing the pre-ablation anatomic map for the
cquisition of new points. A minimum of 5 points per each
ircumferential line was sampled. The end point of the
blation procedure was low peak-to-peak bipolar potentials
0.1 mV) inside the lesion, as determined by local elec-
rographic analysis and voltage maps. Adjunctive ablation
ines were created in the right or left atrium: along the
avotricuspid isthmus (with electrophysiologic assessment
f transisthmic block), and along the isthmus between the
itral annulus and left inferior PV (without electrophysi-
logic assessment of transisthmic block). At the end of the
rocedure, electrical cardioversion was performed if sinus
hythm was not obtained during ablation.
tatistical analysis. Continuous variables are expressed as
he mean value  SD and were compared using the
Abbreviations and Acronyms
AF  atrial fibrillation
ECG  electrocardiogram
PV  pulmonary vein
RCA  radiofrequency catheter ablation
TT  transtelephonicwo-tailed Student t test for paired and unpaired data. A aalue of p 0.05 was considered statistically significant. For
he analysis of atrial arrhythmia recurrence, we considered
he period from one to four months after ablation, during
hich the patients had the TT ECG recorder. Atrial
brillation-free survival data, using standard ECG and
olter recording or TT ECG recordings, were analyzed by
aplan-Meier analysis, and the difference in survival be-
ween groups was examined with by the log-rank test.
ESULTS
linical characteristics. Among the 72 patients enrolled,
3 were male, with a mean age of 62  9.1 years (range 36
o 78 years); 37 patients (51%) had paroxysmal AF; and 35
atients (49%) had persistent AF. Their arrhythmic history
asted a median of four years (range 0.5 to 20 years), and
hey had tried a mean of 3.2  0.8 anti-arrhythmic drugs
range 2 to 5 years). Structural heart disease was present in
0 patients (69%): hypertension in 42 patients, ischemic
eart disease in 5 patients, and valvular disease in 3 patients.
he mean anteroposterior left atrial diameter was 42.4 
.9 mm (range 37 to 55 years), and the mean left ventricular
jection fraction was 58.7  7.6% (range 48% to 75%).
miodarone was prescribed in 49 patients, and flecainide in
3 patients.
apping and ablation procedure. The mean number of
eparate PV ostia mapped per patient was 4.0  0.5 (range
to 6), whereas the mean number of separate PV ostia
ncircled per patient was 3.8 0.7 (range 2 to 6). The mean
rocedure duration was 183.7  64.1 min (range 75 to 295
in), and the mean fluoroscopic exposure was 26.3  8.8
in (range 13 to 59 min). The mean duration of radiofre-
uency applications per patient was 56.4  16.2 min (range
4 to 97 min), and the mean duration of radiofrequency
pplications per isolated PV ostium was 15.4  5.9 min
range 6 to 41 min). Documentation of successful ablation
f all the targeted PVs was obtained in 65 patients (90%).
eft inferior PV-mitral annulus isthmus ablation was per-
ormed in 57 patients (79%), and cavotricuspid isthmus
blation was done in 69 patients (96%). One patient had
ransient phrenic paralysis, and one patient had pericardial
ffusion, which did not require pericardiocentesis.
linical outcome. We obtained 288 standard ECGs, 144
4-h Holter recordings (4 ECGs and 2 Holter recordings
er patient) and 5,585 TT ECG recordings (mean 77.5 TT
CGs per patient). By means of standard ECG and Holter
ecording, 10 patients (13.9%) had an atrial arrhythmia
ecurrence documented. During TT ECG recordings, 20
atients (27.8%) had atrial arrhythmia recurrences (p 
.001) (Fig. 1); of them, 10 had at least one asymptomatic
pisode and eight were completely asymptomatic. Twelve
atients acquired a TT ECG during palpitation (27 epi-
odes), and the rhythm was always AF. No differences in
ny clinical characteristics or anti-arrhythmic drug therapy
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ain study findings. This prospective short-term follow-
p study is the first to use daily TT ECG monitoring, for 90
ays, to document recurrences of AF after catheter ablation.
t demonstrated that half of patients with atrial arrhythmia
ecurrence after catheter ablation have asymptomatic epi-
odes, and using our arrhythmia monitoring strategy, the
uccess rate of AF catheter ablation decreased from 86% to
2%, despite all patients receiving anti-arrhythmic drugs.
hese observations demonstrate that the success rates of
aintaining continuous sinus rhythm in patients with AF
ndergoing ablation therapy are often overestimated. Fi-
ally, on occurrence of palpitations, the patients were able to
etect AF recurrence, as all TT ECGs acquired in this
etting showed an AF episode.
symptomatic AF. Atrial fibrillation is often associated
ith typical symptoms such as palpitations, dizziness, and
yspnea (6,7), but a significant proportion of patients
emain asymptomatic. The prevalence of asymptomatic AF
ncidentally found on clinical examination is 20% (8).
tudies using Holter monitoring, TT monitoring, or event
ecorders (3,9,10) have reported an even higher prevalence.
ecently, using a pacemaker with dedicated function of AF
etection and electrogram storage, Israel et al. (11) reported
8% of patients completely asymptomatic during AF re-
apses lasting more than 48 h. Our study is the first to use
he daily TT ECG, for a period of three months, in
ssessing AF recurrence after catheter ablation. Signifi-
antly, the short-term success rate using TT ECG de-
reased to 72% as compared with 86% (p  0.001), using a
tandard tool to detect AF recurrence, like ECG and 24-h
olter monitoring. In few other series, the TT ECG has
een used to assess the success of AF ablation, and some
uthors have reported different results. In the series of
appone et al. (12), asymptomatic nonsustained AF was
etected in 29 of 300 patients, principally in those with
nown symptomatic late AF (15 patients [50%]). The
ncidence of detected AF in asymptomatic patients was low
14 patients [5%]), and all episodes were nonsustained.
igure 1. Atrial fibrillation–free survival curves using standard electrocar-
iogram and 24-h Holter monitoring (continuous line) or transtelephonic
lectrocardiogram (dotted line) to assess the recurrence of atrial fibrilla-
ion.owever, in this series, the patients were instructed to tbtain a TT ECG once monthly until follow-up ended at
2 months, whereas our patients had a daily TT ECG for
hree months. Recently, Oral et al. (13) evaluated the
ncidence of asymptomatic AF in 60 patients who reported
o symptoms of recurrent AF at 6 months after ablation.
he patients were provided with a patient-activated TT
vent recorder for 30 days, a mean of 645  195 days after
he ablation procedure, and were asked to record and
ransmit the ECG on a daily basis and whenever they felt
alpitations. Seven patients felt palpitations, and each of
hem had an AF episode documented by the event monitor.
mong the 53 asymptomatic patients, an episode of AF was
aptured in one patient (2%) during the study period. The
ower incidence of asymptomatic AF recurrence, as com-
ared with our series, might reflect the shorter period of
ollow-up evaluated (one versus three months) and the
hoice of Oral et al. (13) of scanning 30 days of the
ong-term follow-up rather than 90 days of the short-term
ollow-up, in which the incidence of AF recurrence is
igher (14,15).
linical implications for anticoagulation. Our data seem
o suggest that the true success rate of AF catheter ablation,
sing standard ECG and 24-h Holter monitoring, is
trongly overestimated. Their most important clinical im-
lication is in the management of patients undergoing AF
blation and is related to the need for anticoagulation in
atients with AF (16,17). Physicians usually consider AF as
ured if sinus rhythm is documented on routine ECG or
4-h Holter monitoring, and they often stop anticoagula-
ion. However, short-lasting episodes of atrial arrhythmia,
hich often are asymptomatic, identify patients who are
ore than twice as likely to die or have a stroke (18).
ccording to these findings, we share the view of Kaufman
nd Waldo (1), who suppose that the only patients who do
ot need life-long oral anticoagulation are those without
ssociated risk factors for stroke.
atient symptoms. In our study, we tried to correlate
ymptoms with arrhythmia recurrence. Significantly, 12
atients acquired a TT ECG during palpitation, and the
hythm was always AF. Similar data have been recently
eported by Oral et al. (13); in their series, seven patients felt
alpitations during the study, and each of them had an
pisode of AF documented by the event monitor during
ymptoms. These data suggest that the population of
atients who undergo catheter ablation for drug-refractory
F has a high capacity to recognize the nature of their
ymptoms.
tudy limitations. The study has two major limitations. 1)
he TT ECG lasted only 30 s; so far, we might have lost
ome asymptomatic AF episodes. However, all patients had
ustained and usually long-lasting episodes of AF before
blation, and after ablation, we observed a higher incidence
f persistent AF recurrences instead of paroxysmal recur-
ences, even in asymptomatic patients. 2) In our study, all
atients were taking anti-arrhythmic drug therapy during
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AF Ablation Follow-Up March 15, 2005:873–6rease the incidence of asymptomatic AF recurrences by
roviding rate control during recurrence or by shortening
he duration of the recurrence.
onclusions. Transtelephonic ECG is better than stan-
ard ECG and 24-h Holter recordings in evaluating AF
elapses after RCA, thus decreasing the short-term success
f the ablation from 86% to 72%. The absence of symptoms
hould not be interpreted as absence of AF, as 50% of
atients with recurrences were asymptomatic during at least
ne AF episode.
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